PolyPid Ltd. Q3 2026 Earnings Call Summary Moby Intelligence Wed, November 11, 2026 at 5:16 PM EST 3 min read NVDA -5.21% PYPD +4.60% Trade NVIDIA on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
The NDA for D-PLEX100 is under priority review with labeling discussions underway, indicating the final stages of the regulatory process ahead of the November 28 PDUFA date.
The partnership with Azurity Pharmaceuticals provides immediate commercial infrastructure, including more than 200 personnel and access to more than 1,700 hospitals, mitigating launch execution risk.
Reclaiming European commercial rights from ADVANZ PHARMA allows PolyPid to fully control its regional strategy and capture more value through new potential partnerships.
D-PLEX100's value proposition is driven by a 60% reduction in surgical site infections and a decrease in infection complexity compared to standard care in colorectal procedures.
The expansion into broader abdominal surgeries, representing approximately 4 million annual U.S. procedures, is prioritized to maximize the commercial lifecycle of the D-PLEX platform.
Transitioning from infection prevention to treatment via PD01B leverages the existing D-PLEX safety database and manufacturing infrastructure to accelerate development timelines.
U.S. commercial launch is anticipated in early 2027, with adoption expected to scale account-by-account as hospitals complete individual Pharmacy and Therapeutics committee reviews.
The NTAP reimbursement decision expected in August 2027 is viewed as a secondary catalyst that will simplify hospital formulary adoption rather than serve as a primary driver.
European market entry is targeted for 2028, contingent on an EMA decision expected in the second half of 2027 following the recently validated marketing authorization application.
Cash runway into 2028 assumes modest spending on the PD01B program and relies on milestone payments from the Azurity collaboration and future potential proceeds.
Termination of the ADVANZ PHARMA agreement for Europe reverts all commercial rights to PolyPid, creating a near-term need to secure a new regional partner.
The $15 million milestone payment for NDA acceptance was received in October 2026, providing a post-quarter liquidity boost not reflected in the September 30 cash balance.
Label expansion into broader abdominal surgery depends on upcoming FDA communications in the fourth quarter of 2026 to define the necessary clinical or regulatory requirements.
Management confirmed that labeling discussions are currently underway, which is a standard late-stage requirement for the priority review process.
All scheduled interactions remain aligned with the November 28 PDUFA goal date.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Surgeons highlighted that D-PLEX100 reduced infection rates in open procedures to levels lower than those typically seen in minimally invasive surgeries.
Feedback emphasized that the product not only reduces the number of events but also the complexity and severity of breakthrough infections.
Initial adoption will be a stepwise process over several months as individual hospitals and Integrated Delivery Networks conduct P&T committee reviews.
Market research indicates 90% formulary willingness based on pharmacoeconomic data alone, with NTAP expected to push that to 100% once active in late 2027.
Management declined to provide specific details on the status or findings of pre-approval inspections, citing standard regulatory practice.
They reiterated that all necessary steps to support the regulatory milestone have been initiated or completed.
Existing data on reduced length of stay and infection severity is considered sufficient for P&T committee reviews without the need for new large-scale studies.
Some hospitals may conduct small pilot studies of seven to 10 patients to evaluate operating room workflow and usability rather than clinical efficacy.
